title: Murine models of ovarian cancer for preclinical testing of targeted therapeutics: has their time arrived?
authors.forename: Kathleen R
authors.initials: KR
authors.lastname: Cho
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000378:metabolism; D024682:BRCA2 Protein / Q000378:metabolism; D000068258:Bevacizumab; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D051379:Mice; D009154:Mutation; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D059016:Tumor Microenvironment / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D016159:Tumor Suppressor Protein p53; D000068258:Bevacizumab